Since 1993, the Department of Defense (DoD) has sponsored medical research through a funding mechanism known as the Congressional Directed Medical Research Program (CDMRP)
This program has strong support in the cancer community because it has involved patients and consumers in the peer review process and has funded research of the highest quality. The CDMRP originally focused only on breast cancer and has been expanded to include prostate and ovarian cancer
The DoD program does not include research on the hematological cancers, even though these cancers are common among members of the armed services and there are possible links between certain environmental and occupational exposures for members of the armed services and the development of hematological cancers.
Recommendation for Action
Leukemia, lymphoma and myeloma advocates recommend that Congress expand the DoD Congressional Directed Medical Research Program to include research on hematological cancers.
Blood-related cancers offer important opportunities to explore the cellular mechanisms that will be the answer to the problem of unregulated cancer growth. Research on hematological cancers has often yielded important information regarding treatment of other cancers, including solid tumors, and broadening the DoD program to include leukemia, lymphoma and myeloma will likely yield benefits for all cancer patients.
- LLM advocates urge Senators to sign the letter of Senators DeWine and Reed, endorsing the inclusion of hematological Cancers in the DoD research program.
- LLM advocated urge Representatives to contact Representative Bill young and Representative Jerry Lewis in support of the Crane-Hall proposal to incorporate hematological cancers in the DoD research program.